New anti-tubercular drugs and drug targets are urgently needed to reduce the time for treatment and also to identify agents that will be effective against Mycobacterium tuberculosis persisting intracellularly. Mycobacteria have a unique cell wall. Deletion of the gene for arylamine N-acetyltransferase (NAT) decreases mycobacterial cell wall lipids, particularly the distinctive mycolates, and also increases antibiotic susceptibility and killing within macrophage of Mycobacterium bovis BCG. The nat gene and its associated gene cluster are almost identical in sequence in M. bovis BCG and M. tuberculosis. The gene cluster is essential for intracellular survival of mycobacteria. We have therefore used pure NAT protein for high-throughput screening to identify several classes of small molecules that inhibit NAT activity. Here, we characterize one class of such molecules-triazoles-in relation to its effects on the target enzyme and on both M. bovis BCG and M. tuberculosis. The most potent triazole mimics the effects of deletion of the nat gene on growth, lipid disruption and intracellular survival. We also present the structure-activity relationship between NAT inhibition and effects on mycobacterial growth, and use ligand-protein analysis to give further insight into the structure-activity relationships. We conclude that screening a chemical library with NAT protein yields compounds that have high potential as anti-tubercular agents and that the inhibitors will allow further exploration of the biochemical pathway in which NAT is involved.
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INTRODUCTION
There is an urgent need for new drugs for tuberculosis (TB), and new compounds have been described despite the fact that the targets are not clearly established (Al-Balas et al., 2009) . Discovery of new targets is important to identify novel drugs (Cole and Azari, 2005; Makarov et al., 2009) . It has been recognized that understanding important metabolic pathways is likely to be a useful route towards new therapies (www.tballiance.org) as a result of the success with an ATPase inhibitor (Diacon et al., 2009) . Recent identification of menaquinone biosynthesis as a useful target pathway provides a growing portfolio of potential novel anti-tuberculars (Dhiman et al., 2009) . The need for a wide range of candidate targets and molecular classes is insurance for the future (Maxmen and Barry, 2009; Lin et al., 2009) . The biggest difficulty with anti-tubercular and indeed anti-microbiological agents is the development of resistance. The development of multi-therapies that work in a short time period is an important aim in order to understand more about the organism that causes tuberculosis and also to overcome the disease. Tuberculosis is a global problem compounded by the emergence of drug-resistant tuberculosis particularly in association with AIDS (Dye, 2006) . Whilst tuberculosis is endemic in many developing countries, there are also urban areas in the United Kingdom where TB is now a common disease through the combination of high population density and immigration from countries with endemic TB (Story et al., 2006) . Mycobacterium tuberculosis, the organism that causes TB, survives within macrophage in the host and is likely to be a contributory factor in the extended duration of therapy required for eradication of tuberculosis, as is the existence of persisting, but non-dividing organisms both in and remote from the human lung (Neyrolles et al., 2006) .
Functional genomics has identified possible roles for several previously unknown gene products in M. tuberculosis (Rengarajan et al., 2005) , and investigation of the role of candidate gene products has also resulted in novel functional information. Arylamine N-acetyltransferase (NAT) was initially identified as an interesting target in mycobacterial research because in humans one of the NAT isoenzymes (known as human NAT2) (Boukouvala and Fakis, 2005) had been demonstrated to be responsible for the acetylation and inactivation of the still widely used anti-tubercular drug isoniazid (INH) (Evans et al., 1960; Weber and Hein, 1985) . The discovery of a nat homolog in M. tuberculosis led to the hypothesis that NAT had a role in drug resistance (Payton et al., 1999) . The nat gene is transcribed and the NAT enzyme is active in both M. bovis BCG and M. tuberculosis (Upton et al., 2001) . To investigate drug resistance, a deletion of the nat gene in M. bovis BCG was characterized (Bhakta et al., 2004) . The major target of isoniazid, a pro-drug which is activated inside mycobacteria, has been the subject of dispute, and it is likely that isoniazid has several targets (Raman et al., 2005) . With isoniazid acetylation by NAT competing with activation of the pro-drug by the katG gene product (Nagy et al., 1997; Bhakta et al., 2004) , NAT is likely to be a minor target of isoniazid because deleting the nat gene resulted in a small increase in the sensitivity of the Δnat strain to isoniazid. However, the effect of knocking out the gene was much more dramatic. The effects on the growth, morphology, lipid composition, sensitivity to antibiotics and most importantly the intracellular killing of the Δnat strain of M. bovis BCG within macrophage suggested that the NAT enzyme, per se, would be a useful target for anti-tubercular therapy (Bhakta et al., 2004) . Deletion of the nat gene was the cause of the changes in the genetically modified strain, since complementation of the Δnat strain restored the original phenotype. The observation that the nat gene appears to be essential for survival of M. bovis BCG within macrophage (Bhakta et al., 2004) is consistent with the observation that the nat gene encodes for a protein that is involved in the synthesis of cell wall complex lipids, including mycolates (Bhakta et al., 2004) . It has been shown that the nat gene is encoded as the last gene within an operon (Anderton et al., 2006) . The flanking regions differ by only a single base (in the first gene of the operon) between M. bovis BCG and M. tuberculosis (Fig. 1) . The first two genes of the operon, HsaA and HsaD, have been identified as essential genes for survival of M. tuberculosis within macrophage (Rengarajan et al., 2005) . In addition, inhibitors of the HsaC enzyme encoded by the operon (Fig. 1 ) have a similar effect on the lipid profile as does deletion of the nat gene in M. bovis BCG, that is the mycolates and complex lipids are diminished but the phospholipids are not (Anderton et al., 2006) . More recently, it has become clear that HsaC is essential for survival of M. tuberculosis in the host (Yam et al., 2009) . It has been demonstrated that the operon is part of the KstR regulon that is essential for intracellular survival inside macrophage (Kendall et al., 2007) . The genes encoding HsaA-D have a role in cholesterol catabolism (Van der Geize et al., 2008) and the utilization of propionyl CoA as a cofactor by the TBNATenzyme links the NAT gene product functionally with the operon (Lack et al., 2009) .
To obtain more information on the role of the NAT enzyme as a target for anti-tubercular therapy, a high-throughput screen has been established using recombinant NAT protein (Brooke et al., 2003a, b; Russell et al., 2009 ). The pure recombinant NAT enzyme from M. tuberculosis is relatively insoluble with maximum yields approaching approximately 2 mg per Liter of culture (Upton et al., 2001; Sikora et al., 2008; Lack et al., 2009; Fullam et al., 2009) . In order to optimize the screening procedure, we have therefore used NAT proteins that have similar substrate specificities but are produced more abundantly as recombinant proteins at around 20 mg per liter of culture and that store well when pure (Westwood et al., 2005; Fullam et al., 2007 Fullam et al., ,2009 ). NAT isoenzymes have been characterized from a range of organisms and crystal structures have been obtained for the enzyme from Salmonella typhimurium (Sinclair et al., 2000) , Pseudomonas aeruginosa (Westwood et al., 2005) , the mycobacterial species Mycobacterium smegmatis (Sandy et al., 2002 ) and more recently from Mycobacterium marinum (Fullam et al., 2007; PDB code 2vfb) , which is 74% identical to the enzyme from M. tuberculosis (Fullam et al., 2009) . A preliminary manual screen of a limited range of compounds using the NAT enzyme from M. smegmatis had already proved successful in identifying NAT inhibitors (Brooke et al., 2003b) . We report here that specific NAT inhibitors mimic the effects of deleting the nat gene in M. bovis BCG and that these compounds are also effective in inhibiting the growth of M. tuberculosis.
RESULTS

Screen design
The substrate specificity profiles of NAT enzymes from a range of bacterial NATs are extremely similar to each other but are distinct from the NAT isoenzymes from humans and other mammals (Westwood et al., 2005; Westwood et al., 2006; Kawamura et al., 2005 Kawamura et al., , 2008 . In order to identify compounds that would be unlikely to be metabolized by the human NAT isoenzymes, NAT inhibitors that would be effective against the prokaryotic NAT enzymes but were not inhibitors of the eukaryotic NAT enzymes were sought. NAT enzymes were chosen where sufficient stable recombinant enzyme (tens of milligrams of each protein) was available. The eukaryotic enzymes were pure hamster NAT2 (shNAT2) and its human homolog human NAT1 (hNAT1) (Kawamura et al., 2005; Wang et al., 2005) . The prokaryotic NAT enzymes were from M. smegmatis (Sandy et al., 2002) 
typhimurium (Sinclair et al., 2000) (STNAT) and P. aeruginosa (Westwood et al., 2005 ) (PANAT). The NAT inhibitor screening method is as described previously (Brooke et al., 2003a, b; Russell et al., 2009) . The assay method relies on a colorimetric reaction linked to the NAT-catalysed hydrolysis of acetyl Coenzyme A (acetylCoA), which occurs at a greatly enhanced rate in the presence of a substrate for the acetylation reaction. Conditions for a linear initial rate of acetylCoA hydrolysis were determined for each NAT enzyme included in the screen. Recombinant NAT from M. marinum (MMNAT) was also used for quantitative analyses of compounds as specific prokaryotic NAT inhibitors following the screening process, and a crystal structure for the M. marinum enzyme is also now available (Fullam et al., 2007) .
Inhibition of the hydrolysis of acetylCoA was determined using a library of 5000 drug-like compounds (Russell et al., 2009) . The compounds in the library had been compiled to represent a structurally diverse set of chemically tractable entities without reactive groups such as aldehydes, Schiff bases or aminals, or known cytotoxic agents (such as polynitro aromatics). The structures are also amenable to both resynthesis and rapid diversification (Russell et al., 2009) . Each compound was screened in triplicate against each enzyme with two substrates. Hits in the screen were compounds that inhibited, with both substrates, at least two of the prokaryotic NAT enzymes more than 50% at 30 µM and that did not inhibit either of the eukaryotic NAT enzymes more than 20% at the same concentration. This was also coupled with Z-score analysis to compensate for any systematic errors related to plate position (Brooke et al., 2003a) . The strategy used was designed to maximize the hit rate and to minimize both false-positive and false-negative results.
Protein & Cell Figure 1 . The 'nat' operon in Mycobacterium tuberculosis and Mycobacterium bovis BCG. The genome sequences of M. tuberculosis H 37 Rv and M. bovis BCG are identical in the region shown, except for one nucleotide change in the putative oxidoreductase gene (HsaA) . This nucleotide change leads to an aspartic acid residue in M. bovis BCG where the corresponding amino acid in M. tuberculosis H 37 Rv is an asparagine . The accession numbers for the genes, ordered from hsaA to hsaB, for M. tuberculosis H 37 Rv are: Rv3570c, Rv3569c, Rv3568c and Rv3567c. Rv3570c and Rv3569c have been shown to be essential for survival inside macrophage (Rengarajan et al., 2005) and in vivo (Yam et al., 2009 ). The corresponding genes in M. bovis BCG have the following accession numbers: Mb3601c, Mb3600c, Mb3599c and Mb3598c. The nat gene (Rv3566c, Mb3596c), which has also been shown to be required for survival inside macrophage (Bhakta et al., 2004) , is preceded by a gene encoding for a hypothetical protein (Rv3566a, Mb3597c).
Using this screening strategy, a number of structurally distinct small molecules were identified as hits. The sultam inhibitors, which were identified in the previous one-enzyme screen (Brooke et al., 2003b) , did not appear as hits in this more discriminating five-enzyme screen. In order to confirm the inhibitory activity, the hits were re-screened using more stringent criteria against the same panel of five NAT enzymes. Only compounds that satisfied the criteria of showing over 80% inhibition of at least two prokaryotic enzymes and showing less than 20% inhibition of the eukaryotic enzymes at 30 μM in the re-screen were carried forward ( Fig. 2) . At the completion of the second round of screening, of the six compounds that were identified in distinct chemical classes, two compounds were weak NAT inhibitors upon retesting with the M. marinum NAT enzyme such that less than 80% inhibition was found at 30 µM. Neither of these compounds was therefore pursued further.
For the compounds that were investigated further, effects on growth of M. tuberculosis H37Rv and M. bovis BCG on agar have been determined (Anderton et al., 2006) . Table 1 shows data for the remaining four compounds: compound 1 inhibits PANAT at less than 10 μM but is less effective against the M. marinum enzyme. It is not a good inhibitor of growth of M. tuberculosis and therefore this compound was not pursued further. Of the three remaining compounds, pyrazole 2 had an IC 50 of 18.5 ± 1.0 µM against M. marinum NAT and had an MIC of less than 10 µg/mL against both M. bovis BCG and M. tuberculosis (Table 1 ). In addition, compound 3 was observed to inhibit MMNAT with an IC 50 of 6.0 ± 1.0 µM and to inhibit the growth of M. bovis BCG and M. tuberculosis with a minimum inhibitory concentration (MIC) of less than 5 µg/mL. Compound 3 had previously tested positive as an anti-tubercular agent in an extensive survey of 240 compounds, but no mechanistic information was provided (Jeney et al., 1956) . Compound 4, a 1,2,4 triazole-3-thione derivative, was shown on resynthesis to have an IC 50 of 6.4 μM with PANAT and around 10 μM with MMNAT and to inhibit growth of M. tuberculosis with an MIC of less than 10 μg/ml. We have concentrated on compounds 3 and 4. Since compound 3 has a chiral centre, the present study describes the analysis of compound 4 and its analogues on NAT and M. tuberculosis. Structures incorporating the 1,2,4-triazole-3-thione motif and related examples (Macaev et al., 2005; Foroumadi et al., 2006) have been reported recently to have anti-tubercular activity although no mechanism of action has been proposed.
To summarize, a series of compounds that inhibit bacterial NAT were shown to suppress growth of M. tuberculosis at 10 µg/mL or lower concentration, and we report here on a detailed analysis of the 1,2,4-triazole-3-thione derivative (compound 4).
Compound 4 and its structural analogues
All of the compounds shown in Table 1 were resynthesised to confirm their identity, but we focus here on the resynthesis of compound 4 and a series of analogues. Compound 4 was synthesised as follows: p-tolyl chloride was condensed with thiosemicarbazide in pyridine (Kane et al., 1994; Singh, 1996) . Cyclisation of the condensation product was effected by subsequent treatment with 1 M aqueous sodium bicarbonate to produce the precursor 5-(4'-methylphenyl)-1,2,4-triazole-3-thione (5) in 62% yield and 97% purity over two steps. Alkylation of 5 with methyl 3-bromopropionate produced the target methyl ester (4) in 52% isolated yield (Scheme 1).
Methyl ester 4 was subjected to saponification with lithium hydroxide. The free acid formed (6) was found to be a weaker inhibitor of NAT activity than 4 (IC 50 value of 20.1 ± 0.9 µM), and showed no inhibition of the growth of M. bovis BCG in vitro at any of the concentrations tested (up to 100 µg/mL).
The substituents at both the 3-position and the 5-position of the 1,2,4-triazole ring of 4 were varied to allow preliminary investigations into the structure-activity relationships. Consequently, a range of 1,2,4-triazole-3-thiones (7-12) was synthesised from their corresponding acid chlorides. With the exception of compound 7, the purified yields varied between 44% and 98% ( Table 2 ). The purity of all synthesised compounds was > 95%, as assessed by HPLC (described in Materials and Methods). The 1,2,4-triazole-3-thiones were then treated with a range of electrophiles to generate an array of compounds with a range of substituents on the 3-position of the 1,2,4-triazole ring. An excess of the electrophile was used in order to drive the reaction to completion. Unreacted electrophile was subsequently removed by adding a nucleophilic scavenger resin, in order to avoid the need for further purification steps (Ley, 2000) . Therefore, treatment of the crude reaction mixtures with polymer-supported (Table 1 ) was tested at 30 μM against five NATenzymes from M. smegmatis (MSNAT), S. typhimurium (STNAT), Pseudomonas aeroginosa (PANAT) and also against two eukaryotic enzymes, hamster NAT2 (shNAT2) and human NAT1. In each case pure recombinant enzyme was tested and the results are shown as the mean +/-SD of triplicate determinations of percentage inhibition of hydrolysis of acetylCoA in the presence of arylamine substrate as described in Materials and Methods. methylthiourea (for activated electrophiles) or polymersupported thiophenolate (for non-activated electrophiles) furnished the S-substituted 1,2,4-triazoles 13-18 in 18%-45% isolated yield and > 95% purity (Table 2) .
Compound 4 exhibited competitive inhibition of NAT with respect to the substrate p-anisidine (ANS) at inhibitor concentrations of up to 10 µM (Fig. 3A) and the inhibition constant, K ic , was found to be 6.0 ± 0.3 µM (Fig. 3B) . The synthetic precursor to compound 4, 1,2,4-triazole-3-thione, 5, showed very similar inhibitory properties (Table 2) with competitive inhibition at concentrations up to 10 µM, with a K ic value of 8.6 ± 0.5 µM.
Protein & Cell MIC against M. tuberculosis (µg/mL) 1 17.7 ± 1.5 33.0 ± 1.5 50 2 9.7 ± 0.3 18.5 ± 1.0 < 10 3 11.0 ± 0.7 6.0 ± 1.3 < 5 4 6.4 ± 0.2 10.6 ± 0.5 < 10
Note: NAT inhibitors were identified through a high-throughput screen of a 5000-strong library of drug-like small molecules (Russell et al., 2009 ) with a panel of three pure recombinant prokaryotic NAT enzymes (NATs from Mycobacterium smegmatis, Salmonella typhimurium and Pseudomonas aeruginosa) and two eukaryotic NAT enzymes (human NAT1 and hamster NAT2). The minimum inhibitory concentration (MIC) values against Mycobacterium tuberculosis H 37 Rv of NAT inhibitors identified from the high-throughput screen were determined as described (Anderton et al., 2006) . Determinations of IC 50 values with pure recombinant PANAT and MMNAT were determined for compounds 1-3 with 5-aminosalicylate as substrate and compound 4 with anisidine.
Scheme 1. Reagents and conditions for production of 4. i, pyridine, RT, 4 h; ii, NaHCO 3 (1 M, aq.), 100°C, 16 h; iii, BrCH 2 CH 2 COOMe (1.2 eq.), polymer-supported methylmorpholine (1.2 eq.), DMF, RT, 72 h. a purity was determined by RP-HPLC.
An aryl substituent at the C5 position on the 1,2,4-triazole ring was found to be essential for inhibition of NAT. For example, 5-tert-butyl-1,2,4-triazole-3-thione (7) showed no inhibition of NAT activity at any concentration tested (up to 50 µM, Table 2 ). Of the 5-aryl-1,2,4-triazoles synthesised, the 4'-methoxyphenyl (8) and 4'-chlorophenyl (9) derivatives were considerably less active as NAT inhibitors than the parent and precursor 4'-methylphenyl compounds, 4 and 5 (Table 2 ). However, the 3'-chlorophenyl-1,2,4-triazole-3-thione (10) showed an increase in activity as a NAT inhibitor relative to the 4'-methylphenyl triazole, with an IC 50 value of 244 ± 30 nM, a 60-fold increase in potency. However, the compounds that possessed a nucleophilic sulfur (where substituent R 2 is H, 5, 7-12, Table 2 ) while not observed to react with DTNB or Coenzyme A, were not pursued further due to their potential non-selective reactivity with intracellular electrophiles.
In exploring the preliminary structure-activity relationships for NAT ligands (Brooke et al., 2003a, b) , we observed that the incorporation of a large hydrophobic substituent markedly improved the ligand potency. To probe this effect further, a series of 1,2,4-triazoles with long chain aliphatic or planar aromatic substituents on sulfur were evaluated. Clear structure-activity relationships could be ascertained among these compounds. The length of the chain of the Ssubstituent was estimated following energy minimization with Chem3D Pro (Cambridgesoft). The assumption was made that the carbon chain exists in an extended conformation where multiple conformations are accessible. The NAT inhibition potency increased with extended chain length up to approximately 10 Å, with the S-4-phenylbenzyl (16) and Soctyl (17) derivatives being the most potent in the series (Fig. 4A) . The S-decyl derivative 18 has an approximate chain length of 13 Å and was a less potent inhibitor of NAT than the shorter-chain S-alkyl derivatives. The IC 50 against NAT of the S-decyl derivative (18) was 13.1 ± 1.1 µM, compared with an IC 50 of 3.8 ± 0.4 µM for the S-octyl-1,2,4-triazole (17).
The simulated annealing of compound 4 and its structural analogs to NAT from M. tuberculosis was then evaluated by docking with the program GOLD (Verdonk et al., 2003) . The . The y-coordinate shows the reciprocal rate of reaction, measured by determining the rate of production of CoA as described previously (Brooke et al., 2003a) . The x-coordinate shows the reciprocal of the substrate concentration. The concentration of inhibitor was varied: 0 (squares), 2.5 µM (diamonds), 10 µM (triangles), or 25 µM (circles). Each point represents the mean ± S.D. from triplicate determinations. The y-intercept gives 1/V max,app , the slope of each line gives K m,app /V max,app and the x-intercept gives K1/K m,app . (B) Secondary plot of K m,app /V max,app on the y-coordinate against inhibitor concentration on the x-coordinate. For competitive and mixed types of inhibition, the slope of the line gives K m /V max and the y-intercept gives K m /(V max × K ic ) (Cornish-Bowden, 1995) , from which the pure competitive inhibition constant, K ic , was found to be 6.0 ± 0.3 µM. NATs from M. marinum and M. tuberculosis share 74% identity and 83% similarity at the amino acid level (Fullam et al., 2007) , and the root mean square deviation between the 1080 backbone peptide atoms of the crystal structure of M. marinum NAT and the equivalent atoms in the model of M. tuberculosis NAT is 0.48 Å. The predicted binding orientation of 4 into the NAT from M. tuberculosis is shown in Fig. 3 . The correlation observed between chain length and NAT inhibitory potency (Fig. 4) was closely matched by the docking scores for the same series of compounds (Fig. 5 ). An increase in the calculated binding affinity was observed in the series: S-methyl (13), S-propyl (14), S-benzyl (15), S-4-phenylbenzyl (16) and S-octyl (17) 1,2,4-triazoles. When the S-substituent was a decyl chain (18), the docking score was lower than for the S-octyl derivative. Fig. 5 shows the relative binding orientations of this series of 1,2,4-triazoles, with compound 4 included for comparison. All except compound 18 were predicted to bind in essentially identical orientations. The major predicted binding interactions between these compounds and the M. tuberculosis NAT protein were very similar to those described above for compound 4: π-stacking of the 1,2,4-triazole ring with Phe 130 and H-bonding of one nitrogen of the 1,2,4-triazole ring with the carbonyl oxygens of the 'P-loop' residues, Phe 130 and Gly 131 (Sinclair et al., 2000) . The 4'- bovis BCG and the inhibition of NAT activity with the S-substituent chain length of a series of S-alkyl 1,2,4-triazoles. For each compound in the series, the IC 50 (n) of the compound with NAT from P. aeruginosa was determined as previously described (Brooke et al., 2003a) . The minimum inhibitory concentration (MIC), determined as previously described with M. bovis BCG (Anderton et al., 2006) is also shown (▲). methylphenyl group in all molecules (except the S-decyl derivative 18) was predicted to point towards the active site cysteine residue, as described for 4, above.
Inhibition of growth of M. bovis BCG and M. tuberculosis
The series of 1,2,4-triazole-3-thiones was tested for inhibitory effects on the growth of M. bovis BCG and M. tuberculosis
H37Rv. There was excellent correlation between the inhibitory effects on the growth of both organisms (Fig. 4B) , and for all compounds there appeared to be greater potency in inhibition of M. tuberculosis growth. The growth inhibitory effects were specific, since there was no inhibition of growth of E. coli cultures at up to 100 μg/mL (Fig. 4C) . Compound 4 was a modestly potent inhibitor of both NAT activity and the growth of mycobacteria. The relationship between inhibition
Protein & Cell of NAT activity and inhibition of growth of M. bovis BCG by compound 4 and its structural analogs was investigated. Carboxylic acid 6 was an inhibitor of the NAT enzyme in vitro. However, 6 was found not to be an inhibitor of mycobacterial growth. This may be due to poor cell wall permeability of the carboxylate salt of 6, which is expected to be the predominant form of 6 under the assay conditions. In contrast, there was good correlation between inhibitory potency against NAT and mycobacterial growth inhibition for the remaining Ssubstituted analogues of compound 4 (Fig. 4) . Inhibitory activities on both the NAT enzyme and on growth of M. bovis BCG were affected similarly by the length of the S-substituent, with maximum inhibition corresponding to an extended chain length of around 9 to 10 Å.
NAT inhibitors mimic the effects of Δnat strain
Compound 4, which is a competitive inhibitor of NAT at less than 10 µM, was a good inhibitor of the growth of M. bovis BCG on agar. Treatment of M. bovis BCG with compound 4 resulted in a major effect on the lipid composition ( Fig. 6C-E ).
The effect was very similar to that observed when the nat gene was deleted (Bhakta et al., 2004) : there was a diminution in the amount of the mycolic acids and complex lipids, although the phospholipid composition appeared to be relatively unchanged (Fig. 6 ). In addition, it was observed that compound 4 acted synergistically with gentamycin, mimicking the effect of the genetic deletion of nat in M. bovis BCG. Gentamycin alone is not inhibitory against the growth of wildtype M. bovis BCG at 10 µg/mL (Fig. 6B ), but does affect the growth of the Δnat strain of M. bovis BCG at 10 µg/mL (Bhakta et al., 2004) . In order to determine whether NAT inhibitors would also be active on the intracellular growth of M. bovis BCG, the effects were tested initially on macrophages alone. Compound 4 was not toxic to macrophages (Fig. 6F) . However, when macrophage were infected with M. bovis BCG that had been exposed to compound 4, the bacilli were killed within the macrophage, as has been demonstrated with the Δnat strain (Fig. 6G) (Bhakta et al., 2004) . The same effects were observed at the highest concentration when compound 4 was added after the macrophages had been infected (data not shown).
DISCUSSION
There is an urgent need for novel therapies for tuberculosis, and here we report a new potential drug target in M. tuberculosis: the arylamine N-acetyltransferase enzyme. Following from previous work on genetic deletion of the nat gene in M. bovis BCG (Bhakta et al., 2004) , we now report on the identification and anti-mycobacterial activity of novel small-molecule inhibitors of NATs. From high-throughput screening, we have identified four compounds from chemically distinct structural classes that are active both as inhibitors of purified prokaryotic NAT enzymes and as inhibitors of the growth of M. tuberculosis.
We have synthesised an array of analogs of one of these high-throughput screening hits, the 1,2,4-triazole 4. Structureactivity relationships were identified for a series of Ssubstituted 1,2,4-triazole-3-thiones where the S-substituent was an aliphatic or planar aromatic group. These structureactivity relationships show that the maximal NAT inhibitory activity occurs when the S-substituent extended chain length is around 9-10 Å (Fig. 4) . A similar pattern of interaction between a series of substrates (4-alkoxyanilines) and NAT from M. smegmatis has also been observed (Brooke et al., 2003b) . These NAT substrates/ligands were shown to have anti-tubercular activity although by an unexplained mechanism (Nodzu et al., 1954) . For the 1,2,4-triazole series described (Table 2 , Fig. 4 ), the increase in alkyl chain length allows for more enthalpically favorable hydrophobic contacts within the active site, at the expense of an increasing entropic penalty for binding to the protein. The in silico docking experiments successfully predict the observed structureactivity relationships for the 1,2,4-triazole series (Fig. 5) , and provide a rationale for the observed trends in decreased NAT inhibitory potency when the alkyl chain length is ten carbon units. Binding energy is most favorable and NAT inhibitory potency is maximal when the chain length is equivalent to eight carbons. Furthermore, the structureactivity relationships observed for inhibition of mycobacterial growth mirrored those for NAT inhibition. The availability of NAT inhibitors also allows for studies to investigate the role of NAT in mycobacterial cell wall synthesis and we are pursuing both the class that we describe here and the other classes of inhibitor that we have identified.
Recently, efficient methods for generating sufficient amounts of the NAT enzyme from M. tuberculosis have been identified (Sikora and Blanchard, 2008; Fullam et al., 2009 ) and the enzyme shows a very similar substrate specificity profile to the NAT enzyme from M. marinum (Fullam et al., 2009) . The studies presented here where NAT has been used in a high-throughput screen have identified compounds that have anti-tubercular activity and the triazoles affect mycobacteria within macrophage. These studies also demonstrate an inhibitory effect on growth on agar, whilst the nat deleted mutant strain of M. bovis BCG does show slower growth. Although the nat gene does not appear to be essential for growth on agar, it does appear to be essential for survival of M. bovis BCG inside macrophage. Whilst these studies do not eliminate the possibility that the inhibitors may also act against an additional target in mycobacteria, they suggest that this approach has identified a novel series of compounds to pursue as anti-tubercular agents. The recent finding that the other genes of the operon in which NAT is encoded are essential for survival in vivo (Yam et al., 2009) and the observation of the role of the gene Figure 6 . Effect of NAT inhibitors on the growth of mycobacteria. (A) M. bovis BCG cultures grown in the presence of compound 4 at the concentrations indicated (from 0 to 100 µg/mL in each well). The experimental procedure is described in Materials and Methods. (B) M. bovis BCG with 4 as in (A) but also with gentamycin in each well at a concentration of 10 µg/mL, including the well (0) with DMSO and no compound 4. (C-E) The mycolate profile of M. bovis BCG is altered when grown in liquid culture in the presence of 4 at a concentration of 20 µg/mL. Cells were harvested at mid-exponential phase of growth (optical density at 600 nm = 1.0). Lipid extractions and analyses were carried out with an equivalent biomass of each sample as previously described (Besra, 1998) . The alpha-and keto-mycolic acid methyl esters (MAMEs) of M. bovis BCG (C, lane 1) or M. bovis BCG grown in the presence of 4 (C, lane 2) were analyzed by thin layer chromatography (TLC). Fatty acid methyl esters (FAMES), solvent front (SF) and the origin are indicated. The extracted lipids were also analyzed by two-dimensional TLC with different solvent systems ('D1' and 'E'), as previously described (Besra, 1998) . (D) 2D-TLC plates showing the apolar lipid components run in solvent system 'D1' (Besra, 1998) . Spots corresponding to trehalose dimycolate (Cord Factor, TDM) and glucose monomycolate (GMM) were not present in the lipid extract from M. bovis BCG cells grown in the presence of compound 4. (E) 2D-TLC plates showing the polar lipids run in solvent system 'E' (Besra, 1998) . No effect of compound 4 was observed on the levels of phospholipids (PE, phosphatidylethanolamine; PIM, phosphatidylinositylmannosides). (F) and (G) Compound 4 is not toxic to macrophage RAW 264.7 cells but enhances the killing of M. bovis BCG inside mouse macrophages (RAW 264.7). (F) RAW 264.7 cells were grown in RPMI in the presence of compound 4 (black bars) at 50 μg/mL in DMSO for 72 h at 37°C in a 5% CO 2 incubator. The anti-tubercular drug INH (white bars) was included as a control at a concentration of 50 µg/mL, and a control was included with DMSO alone (hatched bars). In all samples, the final concentration of DMSO was 0.1%. (G) The concentration-dependent effect of compound 4 and INH on the intracellular survival of M. bovis BCG in macrophage cells. The experiment was conducted as described in Materials and Methods. The relative inhibition of growth by 4 and INH was determined by CFU counting and was compared to controls in which DMSO only was added. The final concentration of DMSO in all experiments was 0.1% (v/v). An inhibition of 100% represents no CFUs after incubation of the lysed RAW 264.7 cell contents at 37°C for 21 days.
cluster in cholesterol metabolism (van der Giese et al., 2007; Lack et al., 2009) controlled by the KstR regulon (Kendall and Stoker, 2007) further underline the importance of this group of genes as targets for exploring anti-tubercular agents.
There is a move to identify compounds that affect more than one target and, in the fight against TB, potentially useful targets should not be ignored, especially when the target is important for intracellular survival of mycobacteria within macrophage.
MATERIALS AND METHODS
Protein production and enzymic assays
The NAT enzymes from M. smegmatis (Payton et al., 1999) , S. typhimurium (Sinclair et al., 2000) , P. aeruginosa (Westwood et al., 2005) , M. marinum (Fullam et al., 2007) , hamster NAT2 (Kawamura, 2005) and human NAT1 (Wang, 2005) were produced as recombinant proteins and purified as previously described. Activity assays were performed as previously described (Kawamura, 2005; Brooke, 2003a, b) .
Computational docking of inhibitors with NAT
The program Modeller 8v2 (Sali and Blundell, 1993) was used to construct a model of the TBNAT protein from the known crystal structures of NATs from M. smegmatis (PDB code 1GX3) (Sandy et al., 2002) , S. typhimurium (PDB code 1E2T) (Sinclair et al., 2000) , M. marinum (PDB code 2VFB), P. aeruginosa (PDB code 1W4T) (Westwood et al., 2005) and Mesorhizobium loti NAT1 (PDB code 2BSZ) . A comparison of the model with M. marinum NAT (PDB code 2VFB) is shown in Supplementary Fig. 1 . The protein file was prepared in pdb format by using the AddH tool within the Chimera molecular modeling package (Pettersen et al., 2004) , and docking was performed with GOLD v3.0.1 (Verdonk et al., 2003) . Ligand structures were drawn in ChemDraw (Cambridgesoft) and then converted to 3-dimensional structures in Chem3D. The molecules were energy-minimized with the MM2 force field and saved in sdf format for docking. The active site of the protein was defined by the Sγ atom of Cys 70 with an automatic cavity-detection radius of 20 Å. The docking solutions were ranked with the GoldScore algorithm. Lowest-energy docking solutions were merged with the protein structure and saved in the pdb format, prior to visualization with Aesop as previously described (Sinclair et al., 2000) .
Mycobacterial growth inhibition in vitro
Mycobacteria (M. bovis BCG and M. tuberculosis H37Rv) were grown as spot cultures in 6-well plates on solid medium (Middlebrook 7H10 medium supplemented with 10% (v/v) oleic acid-albumin-dextrosecatalase (OADC)) as previously described (Anderton et al., 2006) , with test compounds at the concentrations indicated in the text. Test compounds were added to the melted, partially cooled 7H10-OADC agar medium as solutions in DMSO, and the final concentration of DMSO in each well was 0.1% (v/v). The minimum inhibitory concentration (MIC) is defined as the concentration of inhibitor at which no growth of mycobacteria was detected after a period of 2-3 weeks. Fig. 5G ) or DMSO alone, prior to infection with M. bovis BCG (5´10 5 mycobacterial cells per well, prepared as described above). After 2 h, the adherent RAW 264.7 cells were washed twice with RPMI, and then resuspended in RPMI containing test compound or DMSO alone (at the concentrations shown in Fig. 5G ). The infected RAW 264.7 cells were cultured for 72 h in RPMI-FBS medium containing either the test compounds or vehicle alone and then washed twice with RPMI alone and lysed by the addition of sterile water. The surviving M. bovis BCG cells in the lysed RAW 264.7 cell suspension were cultured on 7H10-OADC agar medium for 3 weeks at 37°C. The number of colony forming units (CFUs) in each case was determined and used for comparison between tests and controls.
